B Cell News and Research

RSS

Pfizer-BioNTech’s COVID-19 vaccine appears effective against SARS-CoV-2 mu variant

Researchers in Japan have conducted a study showing that the vaccine developed by Pfizer-BioNTech to protect against coronavirus disease 2019 (COVID-19) seems to be adequately effective against the B.1.621 (mu) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

27 Sep 2021

New 'reporter viruses' make it easier to observe SARS-CoV-2 in real time

A version of SARS-CoV-2, the virus that causes COVID-19 disease, has been successfully modified to glow brightly in cells and animal tissues, providing a real-time way to track the spread and intensity of viral infection as it happens in animal models, researchers at Texas Biomedical Research Institute report in the journal The Proceedings of the National Academy of Sciences.

27 Sep 2021

Researchers discover protein previously unknown to be involved in SARS-CoV-2 infection

Researchers in the UK and Germany have provided evidence for a novel mechanism by which severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – binds to human host cells.

27 Sep 2021

Scientists discover novel therapeutic strategy for FLT3-ITD-positive acute myeloid leukemia

A new type of targeting chaperon protein HSP70 inhibitor QL47 was recently discovered by a team led by Prof. LIU Qingsong from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences to treat FLT3-ITD-positive acute myeloid leukemia (AML).

27 Sep 2021

Researchers identify key molecules that may help combat inflammatory diseases

For the first time, researchers have identified key molecules within the immune system that may help fight the inflammation that drives chronic diseases including cancers, sepsis and brain disease.

27 Sep 2021

Third COVID-19 mRNA vaccine booster dose indicated for myelofibrosis patients

A new study discusses the utility of a third booster dose in patients with myelofibrosis.

27 Sep 2021

Monoclonal antibodies may reduce hospital stay, but not mortality in COVID-19

A new study explores the real-world efficacy of monoclonal antibodies against COVID-19 in averting severe disease.

27 Sep 2021

New study clears a pharmacologic hurdle in developing molecularly targeted therapies for AML

New research from Johns Hopkins Kimmel Cancer Center investigators shows why some drugs in clinical trials for treating a form of acute myeloid leukemia (AML) often fail and demonstrates a way to restore their effectiveness.

27 Sep 2021

Chronic COVID-19 and divergent variants of SARS-CoV-2

A new study discusses the isolation of two variants of concern (VOCs) from an immunocompromised COVID-19 patient.

27 Sep 2021

Review of COVID-19 clinical and viral characteristics, pathogenesis, and genetics

A new review article investigates the clinical and viral characteristics, pathogenesis, as well as human genetic basis associated with COVID-19.

27 Sep 2021

Withdrawal from psychostimulants alters functional architecture and patterns in the brain

Addictive psychostimulants, from nicotine in cigarettes to illicit drugs like methamphetamine and cocaine, affect different regions of the brain. The same is believed true during withdrawal; finding a common brain pathway has proved elusive.

27 Sep 2021

Hyperbranched polylysine nanopolymer as potential broad-spectrum antiviral against SARS-CoV-2

The findings from this study suggest that HPNs may inhibit viral replication and budding.

27 Sep 2021

Research reveals new evolutive mechanism of bacteria that expands pathogenic potential

A group of nine researchers has just published new findings on the mechanisms that regulate how bacteria from the Staphylococcus aureus genus transfer genetic material, awarding them greater pathogenic virulence and resistance to antibiotics.

27 Sep 2021

SARS-CoV-2 entry inhibitors show antiviral activity

A new study used a combination of a computer-aided drug design approach and cell-based in vitro assays to identify five potential SARS-CoV-2 inhibitors.

27 Sep 2021

Design of peptide vaccine for SARS-CoV-2

In a recent study, researchers from the US identified two immunogenic non-structural proteins - PLpro and RdRp - from immunodominant gene regions ORF1ab, ORF3a and ORF9b as potential targets for a vaccine against SARS-CoV-2.

27 Sep 2021

B cell activating anti-CD73 antibody for the immunotherapy of COVID-19

Despite the advent of numerous vaccines and the discovery of passive monoclonal antibodies for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), there remains an urgent need for definitive therapies for coronavirus disease-2019 (COVID-19) patients.

27 Sep 2021

Study shows prior COVID-19 and vaccination protects elderly against variants

In order to qualify the risk posed to the elderly, researchers from MUSE University in France began to investigate data from nursing homes that had faced outbreaks from variants of concern. Their work can be found on the medRxiv* preprint server while awaiting peer review.

27 Sep 2021

Scientists develop 'elite' antibodies capable of defeating coronavirus variants at extremely low dosage

Japanese scientists created "elite" antibodies that defeat various coronavirus variants even at an extremely low dose through a new method that accelerated the months-long process of finding such extraordinary antibody candidates to just ten days.

27 Sep 2021

A review of drugs harmful in COVID-19

In a new study, researchers investigate a number of drugs that are believed to potentially worsen outcomes in patients with COVID-19.

26 Sep 2021

Researchers describe a novel role for hnRNP E1 protein in binding DNA in the nucleus

Cancer is a devastating disease and is the second leading cause of death in the U.S. One of the hallmarks of cancer is genomic instability, or the tendency to accumulate mutations and damage to the DNA that leads to genome alterations during cell division.

25 Sep 2021

B Cell News and Research

Pfizer-BioNTech’s COVID-19 vaccine appears effective against SARS-CoV-2 mu variant

New 'reporter viruses' make it easier to observe SARS-CoV-2 in real time

Researchers discover protein previously unknown to be involved in SARS-CoV-2 infection

Scientists discover novel therapeutic strategy for FLT3-ITD-positive acute myeloid leukemia

Researchers identify key molecules that may help combat inflammatory diseases

Third COVID-19 mRNA vaccine booster dose indicated for myelofibrosis patients

Monoclonal antibodies may reduce hospital stay, but not mortality in COVID-19

New study clears a pharmacologic hurdle in developing molecularly targeted therapies for AML

Chronic COVID-19 and divergent variants of SARS-CoV-2

Review of COVID-19 clinical and viral characteristics, pathogenesis, and genetics

Withdrawal from psychostimulants alters functional architecture and patterns in the brain

Hyperbranched polylysine nanopolymer as potential broad-spectrum antiviral against SARS-CoV-2

Research reveals new evolutive mechanism of bacteria that expands pathogenic potential

SARS-CoV-2 entry inhibitors show antiviral activity

Design of peptide vaccine for SARS-CoV-2

B cell activating anti-CD73 antibody for the immunotherapy of COVID-19

Study shows prior COVID-19 and vaccination protects elderly against variants

Scientists develop 'elite' antibodies capable of defeating coronavirus variants at extremely low dosage

A review of drugs harmful in COVID-19

Researchers describe a novel role for hnRNP E1 protein in binding DNA in the nucleus

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News